Drug Trial Radar · NCT05194306
PERTRIAL - Perla® Preservation Solution
Last checked: Nov 20, 2026Latest source record: May 17, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
11
Actual
Start
Dec 11, 2021
Primary completion
Apr 30, 2022
Study completion Apr 30, 2022
Sponsor
- Lead sponsor
- Advanced Life SolutionsIndustry
- Sponsor type
- Industry
- Collaborators
- Complexo Hospitalario Universitario de A Coruña
- First posted
- Jan 18, 2022
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Perla® is a Cold Preservation Solution, with purpose to wash out, preserve during transport liver and kidney grafts in optimal conditions from the donor to the recipient. The purpose of the PERTRIAL clinical investigation is to demonstrate the Performance and Safety of Perla® Cold Preservation solution.
Conditions
- Organ Transplant
- Ischemic Reperfusion Injury
Interventions
Perla® Cold Preservation solutionDrug
Perla® must be cooled to 2° to 6 °C prior to use. The cold Preservation Solution is used to flush the isolated organ immediately before removal from the donor and/or immediately after removal from the donor. The solution is then left in the organ vasculature during hypothermic storage and transportation.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Graft Function Rate (Kidney & Liver)Time frame: 7 days post transplant
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Centro Hospitalario Universitario A Coruña (CHUAC)
A Coruña, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.